Toremifene for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia: Results of a Double-Blind, Placebo Controlled, Phase IIB Clinical Trial
- 30 September 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 176 (3), 965-971
- https://doi.org/10.1016/j.juro.2006.04.011
Abstract
A randomized, double-blind, dose finding, placebo controlled, parallel group clinical study was done to determine the incidence of prostate cancer in men with high grade prostatic intraepithelial neoplasia treated with toremifene. A total of 514 patients with high grade prostatic intraepithelial neoplasia and no evidence of prostate cancer on screening biopsy were randomized to 20, 40 or 60 mg toremifene, or placebo daily for 12 months. Patients underwent re-biopsy at 6 and 12 months. The number of evaluable patients, that is those with 1 on study biopsy who were compliant, was 447. The cumulative risk of prostate cancer was decreased in patients on 20 mg toremifene compared with placebo (24.4% vs 31.2%, p <0.05). The annualized rate of prevention was 6.8 cancers per 100 men treated. In patients with no biopsy evidence of cancer at baseline and 6 months, the 12-month incidence of prostate cancer was decreased by 48.2% with 20 mg toremifene compared with placebo (9.1% vs 17.4%, p <0.05). The 20 mg dose was most effective but cumulative and 12-month incidences of prostate cancer were lower for each toremifene dose vs placebo with a cumulative risk of 29.2% and 28.1%, and a 12-month incidence of 14.3% and 13.0% for 40 and 60 mg, respectively. Gleason scores were similar across treatments. The overall incidence of drug related and serious adverse events did not differ between any of the toremifene groups and the placebo group. Toremifene decreased the incidence of prostate cancer by 1 year and had a tolerability profile comparable to that of placebo in a high risk population.Keywords
This publication has 16 references indexed in Scilit:
- High-grade prostatic intraepithelial neoplasia and prostate cancer risk reductionWorld Journal of Urology, 2003
- Prostatic intraepithelial neoplasiaCurrent Urology Reports, 2000
- EFFECT OF NEOADJUVANT HORMONAL THERAPY ON PROSTATIC INTRAEPITHELIAL NEOPLASIA AND ITS PROGNOSTIC SIGNIFICANCEJournal of Urology, 1999
- Evolution of isolated high-grade prostate intraepithelial neoplasia in a Mediterranean patient population.European Urology, 1999
- Molecular biology of prostatic intraepithelial neoplasiaThe Prostate, 1996
- Prospective origins of prostate carcinoma: Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasiaCancer, 1996
- Expression of estrogen receptor in diseased human prostate assessed by non‐radioactive in situ hybridization and immunohistochemistryThe Prostate, 1995
- High grade prostatic intraepithelial neoplasia. The most likely precursor of prostate cancerCancer, 1995
- Prostatic intraepithelial neoplasia: A premalignant lesionHuman Pathology, 1992
- Androgen‐supported estrogen‐enhanced epithelial proliferation in the prostates of intact noble ratsThe Prostate, 1989